Advertisement

Impact of a previous cancer history on the overall survival of patients with primary gastric cancer: A SEER population-based study

  • Yuqian Chen
    Affiliations
    Department of Gastroenterology, Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine, Nanjing, 210014, Jiangsu, China
    Search for articles by this author
  • Rong Sun
    Affiliations
    Department of Gastroenterology, Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine, Nanjing, 210014, Jiangsu, China
    Search for articles by this author
  • Wanli Liu
    Correspondence
    Corresponding author. Department of Gastroenterology, Nanjing Integrated Traditional Chinese and Western Medicine Hospital affiliated with Nanjing University of Chinese Medicine, No.179 Xiaolingwei, Xuanwu District, Nanjing, 210014, Jiangsu, China
    Affiliations
    Department of Gastroenterology, Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine, Nanjing, 210014, Jiangsu, China
    Search for articles by this author

      Abstract

      Background

      The impact of previous cancers on the survival of gastric cancer (GC) patients is still uncertain. To evaluate the impact of a prior cancer history on the overall survival of patients with primary GC.

      Methods

      The Surveillance, Epidemiology, and End Results (SEER) database provided data on patients diagnosed with GC as the first or second primary malignancy between 2010 and 2015 in this retrospective cohort study. Cox proportional hazards models, Kaplan-Meier curves and forest plots were utilized to analyze overall survival. Subgroup analysis was performed based on age, gender, race and prior cancer type.

      Results

      Totally 39,379 were eligible for this study, including 7403 (18.8%) with a previous cancer history. A previous cancer was an independent risk factor for overall survival [hazard ratio (HR) = 1.103, 95% confidence interval (CI): 1.070–1.138]. For GC patients aged 40–60 years (HR = 1.191, 95% CI: 1.084–1.308) and ≥60 years (HR = 1.093, 95% CI: 1.058–1.13) at diagnosis, a previous cancer was significantly associated with worse overall survival. GC patients with previous oral cavity and pharynx cancer (HR = 1.249, 95% CI: 1.038–1.501), respiratory system cancer (HR = 1.177, 95% CI: 1.076–1.286), female genital system cancer (HR = 1.169, 95% CI: 1.011–1.351), or lymphoma cancer (HR = 1.192, 95% CI: 1.023–1.389) had shorter overall survival than GC patients without a previous cancer.

      Conclusion

      A previous cancer adversely affected the overall survival of GC patients. Specifically, GC patients aged ≥40 years, or with oral cavity and pharynx cancer, respiratory system cancer, female genital system cancer, or lymphoma cancer had inferior overall survival. These patients should obtain more attention and get individualized treatment to improve prognosis, and clinical trial eligibility criteria could be reconsidered for particular age and cancer types.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Miller K.D.
        • Nogueira L.
        • Mariotto A.B.
        • et al.
        Cancer treatment and survivorship statistics.
        CA Cancer J Clin. 2019; 69 (2019): 363-385
        • Bluethmann S.M.
        • Mariotto A.B.
        • Rowland J.H.
        Anticipating the "silver tsunami": prevalence trajectories and comorbidity burden among older cancer survivors in the United States.
        Cancer Epidemiol Biomarkers Prev. 2016; 25: 1029-1036
        • Demark-Wahnefried W.
        • Aziz N.M.
        • Rowland J.H.
        • Pinto B.M.
        Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer.
        J Clin Oncol. 2005; 23: 5814-5830
        • Donin N.
        • Filson C.
        • Drakaki A.
        • et al.
        Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.
        Cancer. 2016; 122: 3075-3086
        • Morton L.M.
        • Onel K.
        • Curtis R.E.
        • Hungate E.A.
        • Armstrong G.T.
        The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults.
        Am Soc Clin Oncol Educ Book. 2014; : e57-e67
        • Sung H.
        • Hyun N.
        • Leach C.R.
        • Yabroff K.R.
        • Jemal A.
        Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States.
        JAMA. 2020; 324: 2521-2535
        • Smyth E.C.
        • Nilsson M.
        • Grabsch H.I.
        • van Grieken N.C.
        • Lordick F.
        Gastric cancer.
        Lancet. 2020; 396: 635-648
        • Machlowska J.
        • Baj J.
        • Sitarz M.
        • Maciejewski R.
        • Sitarz R.
        Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies.
        Int J Mol Sci. 2020; 21
        • Arnold M.
        • Park J.Y.
        • Camargo M.C.
        • Lunet N.
        • Forman D.
        • Soerjomataram I.
        Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035.
        Gut. 2020; 69: 823-829
        • Jin S.
        • Pazdur R.
        • Sridhara R.
        Re-evaluating eligibility criteria for Oncology clinical trials: analysis of investigational new drug applications in 2015.
        J Clin Oncol. 2017; 35: 3745-3752
        • Penel N.
        • Lebellec L.
        • Vanseymortier M.
        Reappraisal of eligibility criteria in cancer clinical trials.
        Curr Opin Oncol. 2018; 30: 352-357
        • Zhu K.
        • Lin R.
        • Zhang Z.
        • Chen H.
        • Rao X.
        Impact of prior cancer history on the survival of patients with larynx cancer.
        BMC Cancer. 2020; 20: 1137
        • Jégu J.
        • Belot A.
        • Borel C.
        • et al.
        Effect of previous history of cancer on survival of patients with a second cancer of the head and neck.
        Oral Oncol. 2015; 51: 457-463
        • Zhou H.
        • Huang Y.
        • Qiu Z.
        • et al.
        Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: a pan-cancer analysis of the SEER database.
        Int J Cancer. 2018; 143: 1569-1577
        • Lichtman S.M.
        • Harvey R.D.
        • Damiette Smit M.A.
        • et al.
        Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology-friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group.
        J Clin Oncol. 2017; 35: 3753-3759
        • Kim E.S.
        • Bruinooge S.S.
        • Roberts S.
        • et al.
        Broadening eligibility criteria to make clinical trials more representative: American society of clinical Oncology and friends of cancer research Joint research statement.
        J Clin Oncol. 2017; 35: 3737-3744
        • Smyth E.C.
        • Tarazona N.
        • Peckitt C.
        • et al.
        Exclusion of gastrointestinal cancer patients with prior cancer from clinical trials: is this justified?.
        Clin Colorectal Cancer. 2016; 15: e53-e59
        • Bian X.
        • Wang K.
        • Wang Q.
        • et al.
        The impact of a prior malignancy on outcomes in gastric cancer patients.
        Cancer Med. 2021; 10: 1457-1470
        • Wen L.
        • Yu K.
        • Lu H.
        • Zhong G.
        Impact of prior cancer history on survival of patients with gastric cancer.
        Eur J Surg Oncol. 2021; 47: 2286-2294
        • Cronin K.A.
        • Ries L.A.
        • Edwards B.K.
        The surveillance, Epidemiology, and end results (SEER) program of the national cancer Institute.
        Cancer. 2014; 120: 3755-3757
        • Duggan M.A.
        • Anderson W.F.
        • Altekruse S.
        • Penberthy L.
        • Sherman M.E.
        The surveillance, Epidemiology, and end results (SEER) program and pathology: toward strengthening the critical relationship.
        Am J Surg Pathol. 2016; 40: e94-e102
        • Xie G.D.
        • Liu Y.R.
        • Jiang Y.Z.
        • Shao Z.M.
        Epidemiology and survival outcomes of mucinous adenocarcinomas: a SEER population-based study.
        Sci Rep. 2018; 8: 6117
        • Fujitani K.
        • Yang H.K.
        • Mizusawa J.
        • et al.
        Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
        Lancet Oncol. 2016; 17: 309-318
        • Slagter A.E.
        • Jansen E.P.M.
        • van Laarhoven H.W.M.
        • et al.
        CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
        BMC Cancer. 2018; 18: 877
        • Yu J.
        • Huang C.
        • Sun Y.
        • et al.
        Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial.
        JAMA. 2019; 321: 1983-1992
        • Laccetti A.L.
        • Pruitt S.L.
        • Xuan L.
        • Halm E.A.
        • Gerber D.E.
        Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.
        J Natl Cancer Inst. 2015; 107
        • Pan D.
        • Xu W.
        • Gao X.
        • Yiyang F.
        • Wei S.
        • Zhu G.
        Survival outcomes in esophageal cancer patients with a prior cancer.
        Medicine (Baltim). 2021; 100e24798
        • Al-Husseini M.J.
        • Saad A.M.
        • Mohamed H.H.
        • Alkhayat M.A.
        • Sonbol M.B.
        • Abdel-Rahman O.
        Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria.
        BMC Cancer. 2019; 19: 863
        • Pierce S.R.
        • Stine J.E.
        • Gehrig P.A.
        • et al.
        Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma.
        Gynecol Oncol. 2017; 144: 531-535
        • Morais S.
        • Antunes L.
        • Bento M.J.
        • Lunet N.
        The effect of a gastric second primary cancer on the survival of patients with a previous cancer history.
        Eur J Cancer Prev. 2020; 29: 215-221
        • Andersen A.R.
        • Bjerring O.S.
        • Godballe C.
        • Detlefsen S.
        • Mortensen M.B.
        Secondary oesophageal or gastric cancer in patients treated for head and neck squamous cell carcinoma.
        Dan Med J. 2016; 63
        • Ji F.
        • Yang C.Q.
        • Li X.L.
        • et al.
        Risk of breast cancer-related death in women with a prior cancer.
        Aging (Albany NY). 2020; 12: 5894-5906
        • Liu J.
        • Zhou H.
        • Zhang Y.
        • et al.
        Impact of prior cancer history on the overall survival of younger patients with lung cancer.
        ESMO Open. 2020; 5
        • Bian X.
        • He X.
        • Yang L.
        • Wu W.
        • Li L.
        Prognosis of hepatocellular carcinoma among cancer survivors with other types of primary tumors.
        Dig Dis Sci. 2020; 65: 2140-2147